FDA warns of allergy risk with Merck antipsychotic

	Tweet

The Food and Drug Administration warned on Thursday that serious allergic reactions have been reported with the use of Merck & Co Inc’s antipsychotic drug Saphris.

The agency said the drug’s label has been revised to include information about the risk.

Saphris, first approved in 2009, is used to treat symptoms of schizophrenia and bipolar disorder.

Doctors should closely monitor patients for reactions including anaphylaxis, swelling, low blood pressure and swollen tongue, the FDA said in a notice on its website.

The agency said Saphris should not be used in patients with a known hypersensitivity to the drug and patients should seek emergency medical attention if they develop any signs and symptoms of a serious allergic reaction while taking Saphris.

###

(Reuters)

RELATED STORIES:
J&J recalls drug after glass found in bottle   P&G being sued over Pampers Dry Max diapers   Drug Prescribed for Migraines and Seizures Increases Risk of Kidney Stones   Teens of epileptic moms display poor school performance   Lawyers to meet next week on Merck’s Vioxx - NYT   Research Findings in Allergic and Immunologic Diseases Unveiled   The Possible Dangers of Buying Medicine Online   Bayer delayed warning on cholesterol drug   Abuse of caffeine pills can land you in intensive care   US warns about risks of Boehringer AIDS drug   BP drugs reduce pneumonia risk in stroke patients   Benefits of allergen immunotherapy persist

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]